In contrast to this publication, Buchanan et al., observed a correlation of ADAM17 and progression free survival by using Affymetrix microarray data of grade 1 and 2 serous ovarian cancer patients [42]. The gene discussed is ADAM17; the disease is ovarian serous adenocarcinoma.